Navigation Links
Two Endometrial Cancer Treatments May Not Work

Studies suggest lymph removal, external beam radiation no help against early disease

FRIDAY, Dec. 12 (HealthDay News) -- Removal of the pelvic lymph nodes, as well as external beam radiation, should not be part of routine care for women with early endometrial cancer, two new studies show.

One study looked at removal of pelvic lymph nodes (pelvic lymphadenectomy), in addition to the standard treatments of hysterectomy and removal of both ovaries and both fallopian tubes (bilateral salpingo-oophorectomy -- BSO). Removal of pelvic lymph nodes is used to determine whether or not the cancer is present outside the uterus and as a therapeutic procedure.

This study included more than 1,400 women at 85 centers in four countries. The women, whose cancer was believed to be localized, were divided into two groups -- 704 underwent standard surgery (hysterectomy and BSO, peritoneal washing, and palpitation of para-aortic nodes), while the other 704 had standard surgery plus pelvic lymphadenectomy.

After a median follow-up of about three years, 88 women in the standard surgery group had died, compared with 103 in the pelvic lymphadenectomy group, which translates into a 16 percent greater risk of death. When the researchers looked at the combined chances of death or recurrent cancer, 107 women in the standard surgery group experienced one or the other, compared with 144 in the lymphadenectomy group, which translates into a 35 percent increased risk.

"This randomized trial has shown no evidence of a benefit for systematic lymphadenectomy for endometrial cancer in terms of overall, disease-specific, and recurrence-free survival. This study is one of the largest reported surgical gynecological cancer trials... Pelvic lymphadenectomy cannot be recommended as routine procedure for therapeutic purposes outside of clinical trials," concluded Dr. Ann Marie Swart, of the Medical Research Trials Unit in London, and colleagues.

The second study evaluated the effects of external beam radiotherapy (EBR). This therapy is typically offered to women who've had successful surgery for early endometrial cancer but are at increased risk of cancer recurrence.

The study included 905 women randomly selected to observation (453) or EBR (452) after surgery. EBR was delivered in 20 to 25 daily fractions up to the target dose.

After a median of 58 months follow-up, 68 women in the observation group and 67 in EBR group had died. Overall five-year survival was 84 percent in both groups.

The study found "no evidence of a benefit for external beam radiotherapy for early endometrial cancer at intermediate or high risk of recurrence, in terms of overall, disease-specific, and disease-specific recurrence-free survival. Combining these findings with data from other trials, we can exclude even a very small benefit of radiotherapy on overall survival."

The authors add that, "adjuvant external beam radiotherapy cannot be recommended as part of routine treatment to improve survival for women with early endometrial cancer at intermediate or high risk of recurrence, and brachytherapy [placement of small radioactive pellets near cancer site] might be preferred for local control."

The studies appear online and in an upcoming print issue of The Lancet.

More information

The U.S. National Cancer Institute has more about treatment for endometrial cancer.

-- Robert Preidt

SOURCE: The Lancet, news release, Dec. 13, 2008

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Ovarian and Endometrial Cancer Patients Experience Improved Outcomes When Treated First by a Gynecologic Oncologist
2. Global view shows link between endometrial cancer and vitamin D status
3. Internal radiotherapy better than external for quality of life in endometrial cancer patients
4. More Than $2.4 Million Raised by National Halloween Promotion Partners to Help St. Jude Fight Childhood Cancer
5. Progress Made in Predicting Breast Cancer Risk
6. Risk Info for Breast Cancer Patients Too Confusing
7. HRT Users Who Get Breast Cancer Less Likely to Die
8. Prescription Drug Benefits for Medicare Patients with Cancer to Cost More in 2009
9. Early stage, HER2-positive breast cancer patients at increased risk of recurrence
10. American Cancer Society recognizes international tobacco control leaders
11. National Cancer Institute Selects Ogilvy Public Relations Worldwide for Comprehensive Multi-Year Communications Support
Post Your Comments:
Related Image:
Two Endometrial Cancer Treatments May Not Work
(Date:11/30/2015)... , ... November 30, 2015 , ... GKhair & Tibolli ... the San Juan Beauty Show held on November 8th and 9th at the Puerto ... media personalities, hair artists, renowned beauticians and top of the line fashion journalists. The ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... provider of enterprise Time and Attendance/Workforce Management cloud-based solutions, announced today that ... Program with competencies in the Application Development, demonstrating a “best-in-class” ability and ...
(Date:11/30/2015)... , ... November 30, 2015 ... ... Inc. are pleased to announce their strategic partnership at the Radiological Society ... Transcription Service, Inc., and Winscribe, global providers of cutting-edge dictation and speech-enabled ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... product dealer. Joining more than 30 HealthPostures’ dealers located throughout the United States, ... increase the number of corporate, industrial, manufacturing and government workers and organizational leaders ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... patented products, announces the Unstoppable Swappables, a household invention that provides an economical ... $2 billion a year and is growing at 2.6%," says Scott Cooper, CEO ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... DUBLIN , Nov. 27, 2015 Research ... of the "Global Intrauterine Devices Market 2015-2019" ... --> In this report, the author ... intrauterine devices market for 2015-2019. To calculate the market ... of following type of products: Hormonal IUDs and copper ...
(Date:11/26/2015)... UTRECHT , Países Bajos, November 26, 2015 /PRNewswire/ ... con la terapia fotodinámica de Bremachlorin para el cáncer ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Un nuevo enfoque combina la inmunoterapia con la ...   Clinical Cancer Research . --> ...
(Date:11/26/2015)... November 26, 2015 ... nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie ... ) --> ... (Photo: ) ... Medisch Centrum (LUMC) blijkt ...
Breaking Medicine Technology: